A Phase 2, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
Phase of Trial: Phase II
Latest Information Update: 31 Jan 2019
At a glance
- Drugs Lixivaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease; Renal failure
- Focus Adverse reactions
- Acronyms ELISA
- Sponsors Palladio Biosciences
- 31 Aug 2018 Biomarkers information updated
- 27 Aug 2018 Status changed from not yet recruiting to recruiting.
- 28 Jun 2018 Planned End Date changed from 1 Mar 2019 to 1 Jun 2019.